ArticleInternational journal of biomedical science : IJBS2014
Bu-shen-he-mai-fang (HMF) Decoction Inhibits Atherosclerosis by Improving Antioxidant and Anti-Inflammatory Activities in ApoE-deficient Mice.
Article in International journal of biomedical science : IJBS, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Study on the Mechanism of Bu-Shen-He-Mai Granules in Improving Renal Damage of Ageing Spontaneously Hypertensive Rats by Regulating Th17 Cell/Tregs Balance.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo observe the effects of Bu-shen- he- mai- fang (HMF) on experimental atherosclerosis in ApoE-deficient mice. MATERIALS AN
methodsThirty male ApoE-deficient mice were randomly divided into 3 groups (10 mice per group) as follows: one group received the standard high- cholesterol diet (high- cholesterol group, HC); Another group received high- cholesterol diet supplemented with HMF decoction 1.37 g/kg/day; the third group received a high- cholesterol diet, supplemented with atrovastatin 5 mg/kg/day for 8 weeks. The extent of atherosclerosis, the expression of LOX-1 protein and macrophage infiltration were evaluated by H&E, oil red O staining, and immunohistochemical staining. SOD was also measured by a spectrophotometer.
resultsThe degree of atherosclerosis was significantly lower in HMF group and atrovastatin group than that in high-cholesterol group. The expression of LOX-1 protein and macrophage filtration were significantly lower in HMF group and atrovastatin group than that in high-cholesterol group. Also, the SOD was higher in HMF group and atrovastatin group than that in high-cholesterol group.
conclusionThe results suggested that HMF significantly inhibited early atherosclerotic lesions by inhibiting inflammatory response and decreasing the generation of ROS.
Indexed as
Identifiers
25598757PMC4289700W1519989754What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.